News
-
Actualités
Time To Get Ready For Rare Disease Day 2021!
TIF joins forces with 300 million people around the world for the global observance of Rare Disease Day, coming up…
Lire la suite » -
Actualités
TIF’s Public Statement on Current Developments in Gene Therapy SCD Clinical Trials and Thalassaemia Gene Therapy Zynteglo
The Thalassaemia International Federation (TIF) has been informed through official communication by both the European Medicines Agency (EMA) and bluebird…
Lire la suite » -
Actualités
-
Actualités
NOW PUBLISHED: The TIF ‘’Gene Therapy & Thalassaemia’’ Survey Report
Gene therapy for thalassaemia is an expensive and complex procedure, with great efforts ongoing currently by all involved stakeholders, such…
Lire la suite » -
Actualités
TIF’s Point of View: Medicines Regulatory Systems – Continued Strengthening Is Required
Access to quality-assured medical products improves health and saves lives. Nevertheless, one third of the world’s population lacks timely access…
Lire la suite » -
Actualités
TIF Supports IAPO´s Call For The Ratification Of The African Medicines Agency Treaty
Two years after the Treaty to establish an African Medicines Agency was agreed, over 40 leading organizations, including the Thalassaemia…
Lire la suite » -
Actualités
The Lancet: Russian Coronavirus Sputnik V Vaccine Achieves Over 90% Efficacy
Russia’s Sputnik V vaccine was 91.6% effective in preventing people from developing Covid-19, according to peer-reviewed results from its late-stage…
Lire la suite » -
Actualités
EMA Accepts MAA For Oxbryta To Treat Haemolytic Anaemia In Sickle Cell Disease
The European Medicines Agency (EMA) has accepted Global Blood Therapeutics (GBT) marketing authorisation application (MAA) for Oxbryta® (voxelotor) for the treatment…
Lire la suite » -
Actualités
TIF Updated Vaccinations & Therapeutic Drugs COVID-19 Guide Has Landed
A comprehensive Guide for both existing and developing vaccines and treatments against COVID-19, exclusively developed by TIF for its global…
Lire la suite »